Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer’s Disease Spectrum
暂无分享,去创建一个
Alzheimer's Disease Neuroimaging Initiative | Bing Liu | L. Tan | Yong Liu | Huifu Wang | T. Jiang | Chen‐Chen Tan | Xiaoke Hao | Jin-Tai Yu | Dao-Qiang Zhang | Ying Liu | Chen‐Chen Tan | Teng Jiang
[1] J. Hardy,et al. Apolipoprotein E in Alzheimer's disease: an update. , 2014, Annual review of neuroscience.
[2] A. Saykin,et al. APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[3] A. Saykin,et al. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. , 2013, Annual review of clinical psychology.
[4] Huaxi Xu,et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.
[5] W. M. van der Flier,et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia , 2013, Neurology.
[6] D. Holtzman,et al. Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide , 2012, The Journal of Neuroscience.
[7] Guojun Bu,et al. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[8] Kewei Chen,et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.
[9] Cindee M. Madison,et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.
[10] David M Holtzman,et al. Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.
[11] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[12] S. Rapcsak,et al. Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers , 2011, Neurology.
[13] Daoqiang Zhang,et al. Multimodal classification of Alzheimer's disease and mild cognitive impairment , 2011, NeuroImage.
[14] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[15] Michael Weiner,et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.
[16] G. B. Frisoni,et al. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.
[17] Norbert Schuff,et al. Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data , 2010, Alzheimer's & Dementia.
[18] W. Chan,et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. , 2010, Archives of neurology.
[19] Owen Carmichael,et al. Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.
[20] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[21] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[22] Michael Weiner,et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.
[23] Sirkka Goebeler,et al. Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.
[24] et al.,et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2009, NeuroImage.
[25] M Schwaiger,et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease , 2009, Neurology.
[26] G. Alexander,et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[27] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[28] W. Jagust,et al. Striatal dopamine and working memory. , 2009, Cerebral cortex.
[29] Katie Hamm,et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.
[30] Sid E O'Bryant,et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.
[31] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[32] C. Jack,et al. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.
[33] Gregory G. Brown,et al. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease , 2005, Neurology.
[34] H C Charles,et al. Impact of APOE in mild cognitive impairment , 2004, Neurology.
[35] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[36] Yaakov Stern,et al. Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E , 2001, Neurobiology of Aging.
[37] Hilkka Soininen,et al. Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.
[38] Mark S. Cohen,et al. Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.
[39] S. Resnick,et al. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype , 2000, Neurology.
[40] P. Scheltens,et al. Apolipoprotein E ϵ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias , 1999 .
[41] P. Scheltens,et al. Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. , 1999, Archives of neurology.
[42] L. S. Steijns,et al. [Apolipoprotein E polymorphism and Alzheimer disease]. , 1996, Tijdschrift voor gerontologie en geriatrie.
[43] D. Galasko,et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. , 1995, Annals of neurology.
[44] S. Gauthier,et al. Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.